A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma (original) (raw)
Journal Article
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Correspondence to: Benny Zee, PhD, Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (e-mail: [email protected] ).
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Jane Koh ,
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Affiliations of authors: Departments of Clinical Oncology (WY, TSM, TWTL, JK, FKFM, ATC, PH, BM, KCL, WMH, HTW, AT), Surgery (PBSL, WYL), and Diagnostic Radiology and Organ Imaging (SCHY), Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China; Comprehensive Cancer Trials Unit, Sir Y. K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China (BZ); Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom (PJJ)
Search for other works by this author on:
Received:
03 February 2005
Revision received:
09 August 2005
Accepted:
09 September 2005
Published:
19 October 2005
Cite
Winnie Yeo, Tony S. Mok, Benny Zee, Thomas W. T. Leung, Paul B. S. Lai, Wan Y. Lau, Jane Koh, Frankie K. F. Mo, Simon C. H. Yu, Anthony T. Chan, Pun Hui, Brigette Ma, Kwok C. Lam, Wing M. Ho, Herman T. Wong, Amanda Tang, Philip J. Johnson, A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma, JNCI: Journal of the National Cancer Institute, Volume 97, Issue 20, 19 October 2005, Pages 1532–1538, https://doi.org/10.1093/jnci/dji315
Close
Navbar Search Filter Mobile Enter search term Search
Abstract
Background: Single-agent doxorubicin has been widely used to treat unresectable hepatocellular carcinoma (HCC), but the response rate is low (<20%) and there is no convincing evidence for improved survival. Cisplatin, interferon, doxorubicin, and fluorouracil (PIAF) used in combination, by contrast, has shown promise in a phase II study. We compared doxorubicin to PIAF in patients with unresectable HCC in a phase III trial. Methods: Patients with histologically confirmed unresectable HCC were randomly assigned to receive either doxorubicin or PIAF every 3 weeks, for up to six cycles. The primary endpoint was overall survival, and secondary endpoints were response rate and toxicity. Survival differences were calculated using the Kaplan-Meier method. Treatment groups were compared for differences in the incidence of adverse events using chi-square tests. All statistical tests were two-sided. Results: The median survival of the doxorubicin and PIAF groups was 6.83 months (95% confidence [CI] = 4.80 to 9.56) and 8.67 months (95% CI = 6.36 to 12.00), respectively ( P = 0.83). The hazard ratio for death from any cause in the PIAF compared with the doxorubicin groups was 0.97 (95% CI = 0.71 to 1.32). Eighty-six of the 94 patients receiving doxorubicin and 91 of the 94 receiving PIAF were assessable for response. The overall response rates in the doxorubicin and PIAF groups were 10.5% (95% CI = 3.9% to 16.9%) and 20.9% (95% CI = 12.5% to 29.2%), respectively. Neutropenia, thrombocytopenia, and hypokalemia were statistically significantly more common in patients treated with PIAF than in patients treated with doxorubicin. Conclusion: Although patients on PIAF had a higher overall response rate and better survival than patients on doxorubicin, the differences were not statistically significant. PIAF was also associated with increased treatment-related toxicity. The prognosis of patients with unresectable HCC remains poor.
© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected].
Topic:
- doxorubicin
- fluorouracil
- combination drug therapy
- cisplatin
- carcinoma, hepatocellular
- phase 3 clinical trials
- interferons
- thrombocytopenia
- human leukocyte interferon
- toxic effect
- frequency of responses
You do not currently have access to this article.
Personal account
- Sign in with email/username & password
- Get email alerts
- Save searches
- Purchase content
- Activate your purchase/trial code
- Add your ORCID iD
Get help with access
Institutional access
Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:
IP based access
Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.
Sign in through your institution
Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.
- Click Sign in through your institution.
- Select your institution from the list provided, which will take you to your institution's website to sign in.
- When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.
Sign in with a library card
Enter your library card number to sign in. If you cannot sign in, please contact your librarian.
Society Members
Society member access to a journal is achieved in one of the following ways:
Sign in through society site
Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:
- Click Sign in through society site.
- When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If you do not have a society account or have forgotten your username or password, please contact your society.
Sign in using a personal account
Some societies use Oxford Academic personal accounts to provide access to their members. See below.
Personal account
A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.
Some societies use Oxford Academic personal accounts to provide access to their members.
Viewing your signed in accounts
Click the account icon in the top right to:
- View your signed in personal account and access account management features.
- View the institutional accounts that are providing access.
Signed in but can't access content
Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.
Institutional account management
For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.
Purchase
Short-term Access
To purchase short-term access, please sign in to your personal account above.
Don't already have a personal account? Register
A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma - 24 Hours access
EUR €39.00
GBP £33.00
USD $43.00
Rental
This article is also available for rental through DeepDyve.